Published by Iain Gilbert on 15th September 2026
(Sharecast News) - Drugmaker GSK said on Tuesday that it would pay up to $750m to acquire full global rights to a trispecific T‑cell engager for multiple myeloma from privately held biotechnology company Chimagen Biosciences.
URL: http://www.digitallook.com/dl/news/story/36210129/...